Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer: a Multicenter, Single-arm, Phase II Clinical Trial.

NCT06261047 is registered in ClinicalTrials.gov with Shandong Cancer Hospital and Institute as lead sponsor.

NCT NCT06261047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06261047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer: a Multicenter, Single-arm, Phase II Clinical Trial.
Lead sponsor
Shandong Cancer Hospital and Institute
Phase
Observational
Overall status
Completed
Start date
March 1, 2024
Completion date
January 1, 2026
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, radiotherapy